The U.S. is expected to maintain the largest share of the market at 65.6 percent. U.S. market revenue is forecasted to increase at a slightly lower CAGR of 3.5 percent from $1.39 billion to $1.78 billion.
The market includes allografts, bone morphogenetic proteins, demineralized bone matrices, synthetic bone substitutes and more.
More Articles on Devices:
Kiva Device for Spinal Fractures Cleared by FDA
Device Companies — 7 Key Notes — Stryker, Orthofix & More
4 Recent Spine & Orthopedic Device Company Expansions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
